Keen to bag the latest NIB dividend? Time is running out

ASX investors will have to be quick if they want to secure NIB's latest dividend…

| More on:
A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • NIB shares are having a tough day today
  • But the health insurance giant is set for another rough day next Monday
  • That's because NIB is scheduled to trade ex-dividend...

It's been a rather sad end to the trading week for the NIB Holdings Limited (ASX: NHF) share price so far this Friday. At the time of writing, NIB shares have endured a 0.99% drop to $8 a share.

That stands in contrast to the broader S&P/ASX 200 Index (ASX: XJO). The ASX 200 has currently banked a tentative gain of 0.08% to around 6,850 points.

It's unclear what is causing investors to have some trepidation about NIB shares as we end the trading week today. But there's one thing we know for sure. The NIB share price is set for another tough day next Monday.

How can we know this? Well, that's when NIB is scheduled to trade ex-dividend for its upcoming final dividend payment.

The NIB dividend is coming, but you'll have to be quick

NIB announced its full-year earnings report for FY22 last month. At the time, the health insurance giant declared a final dividend of 11 cents per share, fully franked. This was a 21.4% decline from the final dividend of 14 cents per share that the company paid out last year for FY21.

It will take NIB's full-year dividends for FY22 to 22 cents per share. That follows April's interim dividend that was also worth 11 cents per share.

Again, that's a drop from FY21's total of 24 cents per share.

But if investors want to receive this dividend, they will have to act quickly. Monday's ex-dividend date means that today is the last day an investor can buy NIB shares to become eligible for this upcoming dividend. From Monday, new shareholders will be cut off.

This is why we are almost certainly set to see NIB shares go backwards during Monday's session. No new investors will be eligible for the final dividend come Monday. As such, the value of this dividend will leave the NIB share price. That's what normally happens when an ASX share goes ex-dividend.

Investors (or those eligible, anyway) will then have to wait until 4 October to see the dividend hit their bank accounts. NIB is offering shareholders the option of participating in the company's dividend reinvestment plan (DRP) though.

So if any investors wish to receive new NIB shares in lieu of cash, they have until 7 September to make this known to the company.

At the current NIB share price, this ASX 200 insurance share has a market capitalisation of $3.67 billion, with a dividend yield of 2.75%.

Should you invest $1,000 in Betashares Nasdaq 100 Etf - Currency Hedged right now?

Before you buy Betashares Nasdaq 100 Etf - Currency Hedged shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Betashares Nasdaq 100 Etf - Currency Hedged wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 3 April 2025

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »

Health professional putting on gloves.
Healthcare Shares

How will Ansell shares navigate tariffs according to Macquarie?

The next two years could be a challenging period for the PPE company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is surging 18% on big news

This stock is getting a lot of love from investors on Monday.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Healthcare Shares

CSL shares are having a tough time recently. Are they a buy or a sell?

Is now a good time to jump in and buy this blue chip star?

Read more »